Abstract 194P
Background
γδ T cells are a small subset (0.5-5%) of peripheral blood T cells playing a key role in both defense against a wide range of pathogens and anticancer immunity. In recent years, Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell malignancies. Although primarily expressed in B-cell lineage cells, BTK expression has also been identified in other cell types. However, the role of BTK expression and the impact of BTK inhibitors on non-B cells, including γδ T cells, remain unclear.
Methods
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats using density gradient centrifugation. Selective γδ T cell expansion was achieved by adding zoledronic acid and IL-2. On day 14 of culturing, ibrutinib, acalabrutinib, or zanubrutinib were introduced. After 48 hours of co-incubation, cytokine production and γδ T cell activation were assessed. To evaluate the impact of BTK inhibitors on γδ T cell activation, HMBPP or the CLL cell line Duller was used as stimulation agents. Cytokine production was evaluated by stimulating the cells with M. tuberculosis lysate, PHA, HMBPP, or anti-CD3 [OKT3], followed by cell permeabilization, staining with specific antibodies, and analysis using flow cytometry.
Results
Ibrutinib significantly reduced the production of IFN-γ and TNF-α by γδ T cells stimulated with HMBPP, but not with Duller cells. This suggests that TCR-independent stimulation pathways, such as through the NK family of receptors, may restore cytokine production to normal levels. No significant differences were found in the production of granzyme B, IL-6, IL-9, IL-10, or IL-17a. All inhibitors reduced the early activation of γδ T cells, as indicated by decreased CD69 expression, while having no effect on late-stage activation. Interestingly, this inhibitory effect was least pronounced with ibrutinib.
Conclusions
BTK inhibitors seem to modulate γδ T cell function, with their impact being pathway-specific and potentially partially reversible depending on the type of stimulation. Moreover, newer inhibitors appear to have a lesser impact on γδ T cells, likely due to their higher specificity for BTK. From an immunotherapeutic perspective, concomitant treatment with BTK inhibitors and in vitro expanded γδ T cells could be a viable option.
Legal entity responsible for the study
Medical University of Lublin.
Funding
DKMS Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract